Zacks Small-Cap Research

September 2, 2013

Steven Ralston, CFA
312-265-9426
sralston@zacks.com

scr.zacks.com

111 North Canal Street, Chicago, IL 60606

University Gen Health Sys (UGHS – OTC)

UGHS - Coverage discontinued

OUTLOOK

Zacks is discontinuing coverage of University General Health System.

Current Recommendation	**Neutral**
Prior Recommendation	Outperform
Date of Last Change	08/30/2013
Current Price (08/30/13)	$0.49
Six- Month Target Price	**$0.49**

SUMMARY DATA

52-Week High	**$0.73**
52-Week Low	**$0.30**
One-Year Return (%)	**22.50**
Beta	**-0.44**
Average Daily Volume (shrs.)	**176,559**
Shares Outstanding (million)	**325.7**
Market Capitalization ($ mil.)	**$160**
Short Interest Ratio (days)	**N/A**
Institutional Ownership (%)	**2**
Insider Ownership (%)	**46.4**
Annual Cash Dividend	**$0.00**
Dividend Yield (%)	**0.00**
5-Yr. Historical Growth Rates	
Sales (%)	**N/A**
Earnings Per Share (%)	**N/A**
Dividend (%)	**N/A**
P/E using TTM EPS	**N/M**
P/E using 2012 Estimate	**49.0**
P/E using 2013 Estimate	**24.5**
Zacks Rank	**3**

Risk Level	**Above Average**
Type of Stock	**Small - Growth**
Industry	**Medical Care**
Zacks Rank in Industry	**12 of 17**

ZACKS ESTIMATES

Revenue
(in thousands of $)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2011	15.4 A	17.9 A	20.7 A	18.5 A	72.5 A
2012	21.7 A	33.0 A	40.8 A	42.5 E	138.0 E
2013					176.0 E
2014					230.0 E

Earnings per Share
(EPS is operating earnings before non-recurring items)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2011	-$0.00 A	-$0.00 A	$0.00 A	-$0.01 A	-$0.01 A
2012	-$0.00 A	$0.01 A	-$0.00 A	-$0.00 E	-$0.01 E
2013					$0.01 E
2014					$0.02 E

Zacks Projected EPS Growth Rate - Next 5 Years % **N/A**


Results originally reported under March FY; results re-arranged as Dec. year.

© Copyright 2013, Zacks Investment Research. All Rights Reserved.

KEY POINTS

- Zacks is discontinuing coverage of University General Health System.

HISTORICAL ZACKS RECOMMENDATIONS



DISCLOSURES

The following disclosures relate to relationships between Zacks Investment Research ("ZIR"), Zacks & Company (ZCO") and Zacks Small-Cap Research ("Zacks SCR") and the issuers covered by the Zacks SCR analysts in the Small-Cap Universe.

ZIR or Zacks SCR Analysts do not hold or trade securities in the issuers which they cover. Each analyst has full discretion on the rating and price target based on their own due diligence. Analysts are paid in part based on the overall profitability of Zacks SCR. Such profitability is derived from a variety of sources and includes payments received from issuers of securities covered by Zacks SCR for non-investment banking services. No part of analyst compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in any report or blog.

ZIR and Zacks SCR do not make a market in any security nor do they act as dealers in securities. Zacks SCR has never received compensation for investment banking services on the small-cap universe. Zacks SCR does not expect received compensation for investment banking services on the small-cap universe. Zacks SCR has received compensation for non-investment banking services on the small-cap universe, and expects to receive additional compensation for non-investment banking services on the small-cap universe, paid by issuers of securities covered by Zacks SCR. Non-investment banking services include investor relations services and software, financial database analysis, advertising services, brokerage services, advisory services, investment research, and investment management.

Additional information is available upon request. Zacks SCR reports are based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Because of individual objectives, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed by Zacks SCR Analysts are subject to change. Reports are not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned.

ZCO and Zacks SCR are separate legal entities. ZCO is U.S. broker-dealer registered with the U.S. Securities and Exchange Commission and a member of the Financial Industry Regulatory Authority and the Securities Investor Protection Corp. This report is for your information only and is not an offer to sell, or a solicitation of an offer to buy, the securities or instruments through ZCO.

Zacks SCR uses the following rating system for the securities it covers. Buy/Outperform: The analyst expects that the subject company will outperform the broader U.S. equity market over the next one to two quarters. Hold/Neutral: The analyst expects that the company will perform in line with the broader U.S. equity market over the next one to two quarters. Sell/Underperform: The analyst expects the company will underperform the broader U.S. Equity market over the next one to two quarters. The current distribution of Zacks Ratings is as follows on the 1,028 companies covered: Buy/Outperform- 14.9%, Hold/Neutral- 78.0%, Sell/Underperform – 6.0%. Data is as of midnight on the business day immediately prior to this publication.